Xi-Ping Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xi-Ping Huang has a total of 533 co-authors. Here are the top co-authors by number of shared publications:
Bryan L. Roth
UNC Chapel Hill School of Medicine
25 shared publications- Bryan L. Roth
Department of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, USA
25 shared publications Vincent Setola
8 shared publications- Brian K. Shoichet
Department of Pharmaceutical Chemistry, University of California, San Francisco
7 shared publications - Vsevolod Katritch
Department of Quantitative and Computational Biology, University of Southern California, Los Angeles, CA 90089, USA
7 shared publications - Raymond C. Stevens
Human Institute, ShanghaiTech University, Shanghai, China
5 shared publications
Latest Publications
- Open Access
- 29 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Structural characterization of kappa-opioid receptor dimer in complex with two G proteins
The κ-opioid receptor (κOR) represents a promising non-addictive analgesic target due to its critical role in pain and reward pathways. Despite evidence of κOR dimerization, its molecular basis and pharmacological significance remain elusive. Here, we demonstrate stable κOR dimer formation in living cells and present cryo-electron microscopy structures of salvinorin A-bound κOR dimer complexed with two Gi proteins, revealing a parallel assembly distinct from previously characterized GPCR dimers that engage only single G protein. Multiple membrane lipids are positioned at the TM1-Helix 8 interface, where they make extensive contacts with both protomers and may contribute to the stability of the κOR dimer. Importantly, dimerization significantly enhances Gi protein recruitment to κOR in both potency and efficacy. We also demonstrate that salvinorin A, a non-nitrogenous agonist, binds similarly in monomeric and dimeric κOR, and identify Y3127.35 as a critical selectivity determinant across opioid receptors. These findings expand our understanding of opioid receptor pharmacology and signaling, providing a foundation for developing superior κOR-targeted therapeutics for pain and related disorders.
- 29 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessStructural characterization of kappa-opioid receptor dimer in complex with two G proteins
The κ-opioid receptor (κOR) represents a promising non-addictive analgesic target due to its critical role in pain and reward pathways. Despite evidence of κOR dimerization, its molecular basis and pharmacological significance remain elusive. Here, we demonstrate stable κOR dimer formation in living cells and present cryo-electron microscopy structures of salvinorin A-bound κOR dimer complexed with two Gi proteins, revealing a parallel assembly distinct from previously characterized GPCR dimers that engage only single G protein. Multiple membrane lipids are positioned at the TM1-Helix 8 interface, where they make extensive contacts with both protomers and may contribute to the stability of the κOR dimer. Importantly, dimerization significantly enhances Gi protein recruitment to κOR in both potency and efficacy. We also demonstrate that salvinorin A, a non-nitrogenous agonist, binds similarly in monomeric and dimeric κOR, and identify Y3127.35 as a critical selectivity determinant across opioid receptors. These findings expand our understanding of opioid receptor pharmacology and signaling, providing a foundation for developing superior κOR-targeted therapeutics for pain and related disorders.
- Top Cited PapersOpen Access
- 13 February 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (7) , eaea9832
Structure-based design of an opioid receptor modulator for enhanced morphine analgesia
The alarming rates of deaths due to opioid overdose present an urgent need for safer opioid analgesics. Positive allosteric modulators (PAMs) of opioid receptors (ORs) offer a promising approach to enhance opioid efficacy while reducing risks of overdose. In this study, we unveil the selective mechanism of PAM modulation of the OR family through structure elucidation of the δ-opioid receptor and μ-opioid receptor (μOR) bound to orthosteric agonists and PAMs BMS986187 (BMS187) and BMS986122 (BMS122). In addition, we uncovered an unexpected but conserved allosteric site across the transmembrane helices TM2 to TM4 of ORs, occupied by BMS187 but not BMS122. Leveraging these structural insights, we designed 9-(5-(4-chlorophenyl)furan-2-yl)-3,3,6,6-tetramethyl-3,4,5,6,7,9-hexahydro-1 H -xanthene-1,8(2 H )-dione (MPAM-15), whose αβ cooperativity factor is 33-fold higher than BMS122 and threefold higher than BMS187, indicating markedly stronger positive allosterism. Animal studies demonstrate that MPAM-15 shows excellent brain penetration and enhances morphine-induced antinociception without exacerbating respiratory depression or constipation. Molecular dynamics simulations revealed that MPAM-15 promotes and stabilizes the conformational equilibrium of μOR toward the canonical active state, providing a mechanistic basis for its enhanced allosteric potency. These discoveries substantially advance our understanding of OR allosteric mechanism and pave the way for the structure-based development of allosteric opioid analgesics.
- 13 February 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (7) , eaea9832
Top Cited PapersOpen AccessStructure-based design of an opioid receptor modulator for enhanced morphine analgesia
The alarming rates of deaths due to opioid overdose present an urgent need for safer opioid analgesics. Positive allosteric modulators (PAMs) of opioid receptors (ORs) offer a promising approach to enhance opioid efficacy while reducing risks of overdose. In this study, we unveil the selective mechanism of PAM modulation of the OR family through structure elucidation of the δ-opioid receptor and μ-opioid receptor (μOR) bound to orthosteric agonists and PAMs BMS986187 (BMS187) and BMS986122 (BMS122). In addition, we uncovered an unexpected but conserved allosteric site across the transmembrane helices TM2 to TM4 of ORs, occupied by BMS187 but not BMS122. Leveraging these structural insights, we designed 9-(5-(4-chlorophenyl)furan-2-yl)-3,3,6,6-tetramethyl-3,4,5,6,7,9-hexahydro-1 H -xanthene-1,8(2 H )-dione (MPAM-15), whose αβ cooperativity factor is 33-fold higher than BMS122 and threefold higher than BMS187, indicating markedly stronger positive allosterism. Animal studies demonstrate that MPAM-15 shows excellent brain penetration and enhances morphine-induced antinociception without exacerbating respiratory depression or constipation. Molecular dynamics simulations revealed that MPAM-15 promotes and stabilizes the conformational equilibrium of μOR toward the canonical active state, providing a mechanistic basis for its enhanced allosteric potency. These discoveries substantially advance our understanding of OR allosteric mechanism and pave the way for the structure-based development of allosteric opioid analgesics.
- Open Access
The selectivity implications of docking libraries with greater and lesser similarities to bio-like molecules
As virtual libraries have expanded into the tens of billions via make-on-demand chemistry, their similarity to metabolites, natural products, and drugs (“bio-like” molecules) has rapidly diminished. Despite this divergence, molecular docking of these ultra-large libraries has yielded molecules at higher experimental hit-rates and with improved affinities. The structural divergence from bio-like space raises the possibility that molecules from these ultra-large libraries have improved selectivity. Just as plausibly, if hit-rates on-target are divorced from similarity to bio-like molecules, so too may be selectivity against off-targets. Here, we test whether docking hits for the 5-HT 2A serotonin receptor from ultra-large libraries are more selective than those from smaller and more bio-like “in-stock” libraries. Chemoinformatic similarity predicts that docking actives from the in-stock library have more off-targets than the more chemically novel hits emerging from docking the ultra-large library. This may reflect the bias of the known, however, as when tested experimentally at scale against 318 GPCRs, both 16 agonists from the ultra-large library and 20 actives from the in-stock library had similar numbers of off-targets. While the ultra-large library hits are more sub-type selective for the 5-HT 2A over the 5-HT 2B and 5-HT 2C receptors, overall these results may suggest that selectivity against off-targets, like affinity and hit-rates for on-targets, is divorced from library similarity to bio-like molecules.
Open AccessThe selectivity implications of docking libraries with greater and lesser similarities to bio-like molecules
As virtual libraries have expanded into the tens of billions via make-on-demand chemistry, their similarity to metabolites, natural products, and drugs (“bio-like” molecules) has rapidly diminished. Despite this divergence, molecular docking of these ultra-large libraries has yielded molecules at higher experimental hit-rates and with improved affinities. The structural divergence from bio-like space raises the possibility that molecules from these ultra-large libraries have improved selectivity. Just as plausibly, if hit-rates on-target are divorced from similarity to bio-like molecules, so too may be selectivity against off-targets. Here, we test whether docking hits for the 5-HT 2A serotonin receptor from ultra-large libraries are more selective than those from smaller and more bio-like “in-stock” libraries. Chemoinformatic similarity predicts that docking actives from the in-stock library have more off-targets than the more chemically novel hits emerging from docking the ultra-large library. This may reflect the bias of the known, however, as when tested experimentally at scale against 318 GPCRs, both 16 agonists from the ultra-large library and 20 actives from the in-stock library had similar numbers of off-targets. While the ultra-large library hits are more sub-type selective for the 5-HT 2A over the 5-HT 2B and 5-HT 2C receptors, overall these results may suggest that selectivity against off-targets, like affinity and hit-rates for on-targets, is divorced from library similarity to bio-like molecules.
- 3 December 2025
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 64 (24) , 4746-4757
Differential Effects of Sodium on Agonist-Induced Conformational Transitions and Signaling at μ and κ Opioid Receptors
Sodium ions are classically conceptualized as negative allosteric modulators for G protein-coupled receptors, although there have been reports of either positive allosteric modulation or no effect of sodium on GPCR function. Here, we identified opposing actions of sodium on μ and κ opioid receptors. We utilized a variety of methods including radioligand binding, real-time conformational monitoring of transitions using bioluminescence resonance energy transfer, and signaling assays using the TRUPATH resource. At the μ receptors, sodium behaved as a negative allosteric modulator of binding, conformational transitions, and signaling. Intriguingly, bitopic μ agonists displayed transducer-specific effects on conformational transitions and signaling sodium concentrations. By contrast, at the κ opioid receptor, sodium negatively modulated agonist binding and positively modulated conformational transitions and signaling. Taken together, these findings support the notion that the differential sensitivities to sodium concentrations will result in opposing effects on the cell surface and intracellular signaling.
- 3 December 2025
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 64 (24) , 4746-4757
Differential Effects of Sodium on Agonist-Induced Conformational Transitions and Signaling at μ and κ Opioid Receptors
Sodium ions are classically conceptualized as negative allosteric modulators for G protein-coupled receptors, although there have been reports of either positive allosteric modulation or no effect of sodium on GPCR function. Here, we identified opposing actions of sodium on μ and κ opioid receptors. We utilized a variety of methods including radioligand binding, real-time conformational monitoring of transitions using bioluminescence resonance energy transfer, and signaling assays using the TRUPATH resource. At the μ receptors, sodium behaved as a negative allosteric modulator of binding, conformational transitions, and signaling. Intriguingly, bitopic μ agonists displayed transducer-specific effects on conformational transitions and signaling sodium concentrations. By contrast, at the κ opioid receptor, sodium negatively modulated agonist binding and positively modulated conformational transitions and signaling. Taken together, these findings support the notion that the differential sensitivities to sodium concentrations will result in opposing effects on the cell surface and intracellular signaling.
- Open Access
Differential effects of sodium on agonist-induced conformational transitions and signaling at μ and κ opioid receptors
Sodium ions are classically conceptualized as negative allosteric modulators for G protein coupled receptors (GPCRs), although there have been reports of either positive allosteric modulation or no effect of sodium on GPCR function. Here we identified opposing actions of sodium on the μ and κ opioid receptors. We utilized a variety of methods including radioligand binding, real-time conformational monitoring of transitions using bioluminescence resonance energy transfer and signaling assays using the TRUPATH resource. At the μ receptors, sodium behaved as a negative allosteric modulator of binding, conformational transitions and signaling. Intriguingly, bitopic μ agonists were unaffected by sodium concentrations. By contrast, at the κ opioid receptor sodium negatively modulated agonist binding and positively modulated conformational transitions and signaling. Taken together, these findings support the notion that the differential sensitivities to sodium concentrations will result in opposing effects on cell surface and intracellular signaling.
Open AccessDifferential effects of sodium on agonist-induced conformational transitions and signaling at μ and κ opioid receptors
Sodium ions are classically conceptualized as negative allosteric modulators for G protein coupled receptors (GPCRs), although there have been reports of either positive allosteric modulation or no effect of sodium on GPCR function. Here we identified opposing actions of sodium on the μ and κ opioid receptors. We utilized a variety of methods including radioligand binding, real-time conformational monitoring of transitions using bioluminescence resonance energy transfer and signaling assays using the TRUPATH resource. At the μ receptors, sodium behaved as a negative allosteric modulator of binding, conformational transitions and signaling. Intriguingly, bitopic μ agonists were unaffected by sodium concentrations. By contrast, at the κ opioid receptor sodium negatively modulated agonist binding and positively modulated conformational transitions and signaling. Taken together, these findings support the notion that the differential sensitivities to sodium concentrations will result in opposing effects on cell surface and intracellular signaling.
- Top Cited Papers
- 5 March 2025
- Published by Springer Nature in Nature
- Vol. 640 (8057) , 265-273
A cryptic pocket in CB1 drives peripheral and functional selectivity
The current opioid overdose epidemic highlights the urgent need to develop safer and more effective treatments for chronic pain1. Cannabinoid receptor type 1 (CB1) is a promising non-opioid target for pain relief, but its clinical use has been limited by centrally mediated psychoactivity and tolerance. We overcame both issues by designing peripherally restricted CB1 agonists that minimize arrestin recruitment. We achieved these goals by computationally designing positively charged derivatives of the potent CB1 agonist MDMB-Fubinaca2. We designed these ligands to occupy a cryptic pocket identified through molecular dynamics simulations—an extended binding pocket that opens rarely and leads to the conserved signalling residue D2.50 (ref. 3). We used structure determination, pharmacological assays and molecular dynamics simulations to verify the binding modes of these ligands and to determine the molecular mechanism by which they achieve this dampening of arrestin recruitment. Our lead ligand, VIP36, is highly peripherally restricted and demonstrates notable efficacy in three mouse pain models, with 100-fold dose separation between analgesic efficacy and centrally mediated side effects. VIP36 exerts analgesic efficacy through peripheral CB1 receptors and shows limited analgesic tolerance. These results show how targeting a cryptic pocket in a G-protein-coupled receptor can lead to enhanced peripheral selectivity, biased signalling, desired in vivo pharmacology and reduced adverse effects. This has substantial implications for chronic pain treatment but could also revolutionize the design of drugs targeting other G-protein-coupled receptors.
- 5 March 2025
- Published by Springer Nature in Nature
- Vol. 640 (8057) , 265-273
Top Cited PapersA cryptic pocket in CB1 drives peripheral and functional selectivity
The current opioid overdose epidemic highlights the urgent need to develop safer and more effective treatments for chronic pain1. Cannabinoid receptor type 1 (CB1) is a promising non-opioid target for pain relief, but its clinical use has been limited by centrally mediated psychoactivity and tolerance. We overcame both issues by designing peripherally restricted CB1 agonists that minimize arrestin recruitment. We achieved these goals by computationally designing positively charged derivatives of the potent CB1 agonist MDMB-Fubinaca2. We designed these ligands to occupy a cryptic pocket identified through molecular dynamics simulations—an extended binding pocket that opens rarely and leads to the conserved signalling residue D2.50 (ref. 3). We used structure determination, pharmacological assays and molecular dynamics simulations to verify the binding modes of these ligands and to determine the molecular mechanism by which they achieve this dampening of arrestin recruitment. Our lead ligand, VIP36, is highly peripherally restricted and demonstrates notable efficacy in three mouse pain models, with 100-fold dose separation between analgesic efficacy and centrally mediated side effects. VIP36 exerts analgesic efficacy through peripheral CB1 receptors and shows limited analgesic tolerance. These results show how targeting a cryptic pocket in a G-protein-coupled receptor can lead to enhanced peripheral selectivity, biased signalling, desired in vivo pharmacology and reduced adverse effects. This has substantial implications for chronic pain treatment but could also revolutionize the design of drugs targeting other G-protein-coupled receptors.
- Open Access
- 5 August 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-18
A neurodevelopmental disorder mutation locks G proteins in the transitory pre-activated state
Many neurotransmitter receptors activate G proteins through exchange of GDP for GTP. The intermediate nucleotide-free state has eluded characterization, due largely to its inherent instability. Here we characterize a G protein variant associated with a rare neurological disorder in humans. GαoK46E has a charge reversal that clashes with the phosphate groups of GDP and GTP. As anticipated, the purified protein binds poorly to guanine nucleotides yet retains wild-type affinity for G protein βγ subunits. In cells with physiological concentrations of nucleotide, GαoK46E forms a stable complex with receptors and Gβγ, impeding effector activation. Further, we demonstrate that the mutant can be easily purified in complex with dopamine-bound D2 receptors, and use cryo-electron microscopy to determine the structure, including both domains of Gαo, without nucleotide or stabilizing nanobodies. These findings reveal the molecular basis for the first committed step of G protein activation, establish a mechanistic basis for a neurological disorder, provide a simplified strategy to determine receptor-G protein structures, and a method to detect high affinity agonist binding in cells.
- 5 August 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-18
Open AccessA neurodevelopmental disorder mutation locks G proteins in the transitory pre-activated state
Many neurotransmitter receptors activate G proteins through exchange of GDP for GTP. The intermediate nucleotide-free state has eluded characterization, due largely to its inherent instability. Here we characterize a G protein variant associated with a rare neurological disorder in humans. GαoK46E has a charge reversal that clashes with the phosphate groups of GDP and GTP. As anticipated, the purified protein binds poorly to guanine nucleotides yet retains wild-type affinity for G protein βγ subunits. In cells with physiological concentrations of nucleotide, GαoK46E forms a stable complex with receptors and Gβγ, impeding effector activation. Further, we demonstrate that the mutant can be easily purified in complex with dopamine-bound D2 receptors, and use cryo-electron microscopy to determine the structure, including both domains of Gαo, without nucleotide or stabilizing nanobodies. These findings reveal the molecular basis for the first committed step of G protein activation, establish a mechanistic basis for a neurological disorder, provide a simplified strategy to determine receptor-G protein structures, and a method to detect high affinity agonist binding in cells.
- 13 May 2024
- Published by Elsevier in Sustainable Cities and Society
- Vol. 109, 105523
A novel framework for the spatiotemporal assessment of urban flood vulnerability
- 13 May 2024
- Published by Elsevier in Sustainable Cities and Society
- Vol. 109, 105523
A novel framework for the spatiotemporal assessment of urban flood vulnerability
- Open Access
Nonspecific membrane bilayer perturbations by ivermectin underlie SARS-CoV-2 in vitro activity
Since it was proposed as a potential host-directed antiviral agent for SARS-CoV-2, the antiparasitic drug ivermectin has been investigated thoroughly in clinical trials, which have provided insufficient support for its clinical efficacy. To examine the potential for ivermectin to be repurposed as an antiviral agent, we therefore undertook a series of preclinical studies. Consistent with early reports, ivermectin decreased SARS-CoV-2 viral burden in in vitro models at low micromolar concentrations, five- to ten-fold higher than the reported toxic clinical concentration. At similar concentrations, ivermectin also decreased cell viability and increased biomarkers of cytotoxicity and apoptosis. Further mechanistic and profiling studies revealed that ivermectin nonspecifically perturbs membrane bilayers at the same concentrations where it decreases the SARS-CoV-2 viral burden, resulting in nonspecific modulation of membrane-based targets such as G-protein coupled receptors and ion channels. These results suggest that a primary molecular mechanism for the in vitro antiviral activity of ivermectin may be nonspecific membrane perturbation, indicating that ivermectin is unlikely to be translatable into a safe and effective antiviral agent. These results and experimental workflow provide a useful paradigm for performing preclinical studies on (pandemic-related) drug repurposing candidates.
Open AccessNonspecific membrane bilayer perturbations by ivermectin underlie SARS-CoV-2 in vitro activity
Since it was proposed as a potential host-directed antiviral agent for SARS-CoV-2, the antiparasitic drug ivermectin has been investigated thoroughly in clinical trials, which have provided insufficient support for its clinical efficacy. To examine the potential for ivermectin to be repurposed as an antiviral agent, we therefore undertook a series of preclinical studies. Consistent with early reports, ivermectin decreased SARS-CoV-2 viral burden in in vitro models at low micromolar concentrations, five- to ten-fold higher than the reported toxic clinical concentration. At similar concentrations, ivermectin also decreased cell viability and increased biomarkers of cytotoxicity and apoptosis. Further mechanistic and profiling studies revealed that ivermectin nonspecifically perturbs membrane bilayers at the same concentrations where it decreases the SARS-CoV-2 viral burden, resulting in nonspecific modulation of membrane-based targets such as G-protein coupled receptors and ion channels. These results suggest that a primary molecular mechanism for the in vitro antiviral activity of ivermectin may be nonspecific membrane perturbation, indicating that ivermectin is unlikely to be translatable into a safe and effective antiviral agent. These results and experimental workflow provide a useful paradigm for performing preclinical studies on (pandemic-related) drug repurposing candidates.
- Open Access
Xylazine is an agonist at kappa opioid receptors and exhibits sex-specific responses to naloxone administration
Xylazine has been found in the unregulated drug supply at increasing rates, usually in combination with fentanyl. It has become critical to understand its basic pharmacology, how it impacts behavior, and how it interacts with fentanyl in rodent models of opioid administration. Despite commentary from scientists, politicians, and public health officials, it is not known if xylazine impacts the efficacy of naloxone, the opioid receptor antagonist used to reverse opioid induced respiratory depression. Furthermore, few studies have examined the effects of xylazine alone, without co-administration of ketamine. Here, we examine the impact of xylazine alone and in combination with fentanyl on several key behaviors in male and female mice. We demonstrate differential locomotor responses by dose and sex to xylazine. Surprisingly, our results further indicate that naloxone precipitates withdrawal from xylazine and a fentanyl/xylazine combination, in both sexes, with enhanced sensitivity in females. Further, we show that xylazine is a full agonist at the kappa opioid receptor, a potential mechanism for its naloxone sensitivity. One-Sentence Summary: We present surprising new insights into xylazine and fentanyl pharmacology with immediate implications for clinical practice and frontline public health.
Open AccessXylazine is an agonist at kappa opioid receptors and exhibits sex-specific responses to naloxone administration
Xylazine has been found in the unregulated drug supply at increasing rates, usually in combination with fentanyl. It has become critical to understand its basic pharmacology, how it impacts behavior, and how it interacts with fentanyl in rodent models of opioid administration. Despite commentary from scientists, politicians, and public health officials, it is not known if xylazine impacts the efficacy of naloxone, the opioid receptor antagonist used to reverse opioid induced respiratory depression. Furthermore, few studies have examined the effects of xylazine alone, without co-administration of ketamine. Here, we examine the impact of xylazine alone and in combination with fentanyl on several key behaviors in male and female mice. We demonstrate differential locomotor responses by dose and sex to xylazine. Surprisingly, our results further indicate that naloxone precipitates withdrawal from xylazine and a fentanyl/xylazine combination, in both sexes, with enhanced sensitivity in females. Further, we show that xylazine is a full agonist at the kappa opioid receptor, a potential mechanism for its naloxone sensitivity. One-Sentence Summary: We present surprising new insights into xylazine and fentanyl pharmacology with immediate implications for clinical practice and frontline public health.